rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Rocket Pharmaceuticals, Inc.

RCKT · Nasdaq

Health CareBiotechnologyNot moving yetSynthetic Biology / TechBio

RCKT stood above a rising 150-day average in 10 of the last 52 weekly readings, and has been out of that trend for the last 14 weeks. It is 35.7% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 14
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$69K
Insider sales, 12 months
$1.7M
Officials’ trades on record
0
Institutions holding
174 (-16)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 10 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$523K$0$174KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months25
Buyers · sellers1 · 6
WhoDidSharesTraded
Martin WilsonGeneral Counselsold75,364at $3.4011 Sep 2026filed 15 Sep 2026
Gaurav ShahCEOsold2,293at $3.3818 Aug 2026filed 20 Aug 2026
Martin WilsonGeneral Counselsold631at $3.3818 Aug 2026filed 20 Aug 2026
Martin WilsonGeneral Counselsold3,493at $3.3813 Aug 2026filed 17 Aug 2026
Gaurav ShahCEOsold2,837at $3.3813 Aug 2026filed 17 Aug 2026
Sarbani ChaudhuriOfficersold4,701at $3.5011 Aug 2026filed 13 Aug 2026
Christopher James StevensChief Operating Officersold36,658at $3.5011 Aug 2026filed 13 Aug 2026
Gaurav ShahCEOsold55,684at $3.0921 May 2026filed 26 May 2026
John MilitelloOfficersold384at $3.0119 May 2026filed 21 May 2026
Martin WilsonGeneral Counselsold662at $3.0119 May 2026filed 21 May 2026
Gaurav ShahCEOsold2,409at $3.0119 May 2026filed 21 May 2026
John MilitelloOfficersold855at $3.6113 May 2026filed 14 May 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders174-16 on the quarter
New · exited21 · 36
Reported value$342.6M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
RTW INVESTMENTS, LPunchanged · filed 14 Aug 202617,687,772$60.5M00.0%
BlackRock, Inc.added · filed 7 Aug 20269,923,962$33.9M+2,089,167+26.7%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 20265,810,033$19.9M+1,119,818+23.9%
CITIGROUP INCreduced · filed 3 Aug 20264,865,551$16.6M-242,157−4.7%
MARSHALL WACE, LLPadded · filed 13 Aug 20264,029,262$13.8M+990,547+32.6%
MILLENNIUM MANAGEMENT LLCadded · filed 14 Aug 20264,000,344$13.7M+882,220+28.3%
Newtyn Management, LLCadded · filed 14 Aug 20264,000,000$13.7M+834,100+26.3%
MAVERICK CAPITAL LTDadded · filed 14 Aug 20263,923,963$13.4M+356,591+10.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20263,784,387$12.9M+8,651+0.2%
AQR CAPITAL MANAGEMENT LLCadded · filed 14 Aug 20263,386,162$11.6M+316,232+10.3%
31 Mar 2023 – 30 Jun 2026
134172210Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Martin Wilson Company insiderGeneral Counsel · last 11 Sep 20260 · 19
Gaurav Shah Company insiderCEO · last 18 Aug 20262 · 21
Christopher James Stevens Company insiderChief Operating Officer · last 11 Aug 20260 · 1
Sarbani Chaudhuri Company insiderOfficer · last 11 Aug 20260 · 2
David P. Southwell Company insiderDirector · last 3 Aug 20261 · 5
Carsten Boess Company insiderDirector · last 18 Jun 20260 · 0
Fady Ibraham Malik Company insiderDirector · last 18 Jun 20260 · 0
Mikael Dolsten Company insiderDirector · last 18 Jun 20260 · 0
Peter Fong Company insiderDirector · last 18 Jun 20260 · 0
Roderick Wong Company insiderDirector, 10% owner · last 18 Jun 20260 · 1
John Militello Company insiderOfficer · last 26 May 20260 · 31
Syed Ali-aamir Rizvi Company insiderChief Medical Officer · last 11 Feb 20260 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-77.2%
Share count trendFY 2025 · to 20 Feb 20260.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$77.6M
Free cash flowFY 2025 · to 31 Dec 2025−$190.5M

Analyst forecasts

No analyst forecasts yet.